北大醫藥(000788.SZ):注射用頭孢米諾鈉藥品註冊申請獲受理
格隆匯5月14日丨北大醫藥(000788.SZ)公佈,近日,公司藥品注射用頭孢米諾鈉,一致性評價補充申請獲得國家藥品監督管理局藥品審評中心正式受理。
頭孢米諾為頭黴素衍生物,屬於第二代頭孢菌素,具有抗菌譜廣、殺菌力強、適應症多等特點。頭孢米諾對青黴素結合蛋白有極強的親和力,對細菌合成細胞壁起到有效抑制作用,再結合肽多糖,對脂蛋白和肽多糖的結合進行抑制,促進細菌溶解,因而具有強大的殺菌效果。
注射用頭孢米諾鈉臨牀廣泛應用於對頭孢米諾敏感的鏈球菌屬、肺炎鏈球菌、大腸埃希菌、克雷伯菌屬、變形桿菌屬、摩根菌屬、普羅菲登斯菌屬、流感嗜血桿菌、擬桿菌屬、普雷沃菌屬(二路普雷沃菌屬除外)引起的敗血症、扁桃體炎(包括扁桃體周圍膿腫)、急性支氣管炎、肺炎、肺膿腫、慢性呼吸道病變繼發感染、膀胱炎、腎盂腎炎、腹膜炎、膽囊炎、膽管炎、子宮內感染、子宮附件炎、子宮旁組織炎等。
根據米內網數據顯示,注射用頭孢米諾鈉2018年和2019年國內樣本醫院銷售額分別為5.05億元和5.32億元,該產品保持了良好的增長,產品市場空間大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.